420 with CNW — Cannabis Industry Gears Up for a Shake-Up as ‘Gifting’ Shops Transform in D.C.

Medical cannabis dispensaries are rapidly expanding in D.C. as authorities transition former “gifting” stores into licensed operations.

In 2014, D.C. voters passed Initiative 71, which legalized recreational cannabis possession, use, and sharing among adults but prohibited direct sales. However, a loophole allowed businesses to sell non-cannabis products while including marijuana as a complimentary gift. Many consumers preferred this method to avoid being listed in a registry as medical dispensaries required patient registration.

Now these gifting shops had until the end of March to obtain a medical cannabis license or face closure. Before this transition, only eight cultivation facilities and seven dispensaries were officially licensed in D.C. after medical cannabis was legalized in 2010. However, the actual number of shops selling marijuana far exceeded this count. Regulatory enforcement has already resulted in the shutdown of 42 stores.

One such shop, Monko, previously sold items like T-shirts and pens before converting into a licensed medical cannabis dispensary. Owner Terrence White, who has been navigating the licensing process for six months, is preparing to begin legal sales.

His long-term vision includes expanding into a vertically integrated cannabis business. With an estimated customer base of 26,000 in D.C., he believes the transition levels the playing field for legal operators.

Obtaining approval to buy medical cannabis in D.C. is relatively simple as registration is open to anyone over 21, regardless of residency. Visitors can opt for a three-day medical cannabis card for $10 or a year-long card for $100.

The local cannabis industry faced challenges when Maryland expanded access to recreational marijuana in 2023, allowing former medical-only businesses to serve all adults. Many consumers preferred Maryland’s system to avoid appearing in a registry while still purchasing legally.

Unlike other jurisdictions, Washington, D.C., operates under congressional oversight, which has historically prevented local authorities from fully regulating cannabis sales. Congress has also blocked D.C. from allocating tax funds toward legalizing recreational sales.

The presence of gifting shops and competition from Maryland initially made national cannabis brands hesitant to enter the Washington, D.C. market. However, recent regulatory changes have attracted major players.

Cookies has now partnered with Alternate Solutions to establish a presence in the district, while Khalifa Kush has been collaborating with District Cannabis for over a year.

With gifting shops disappearing, licensed dispensaries anticipate better business prospects. Although D.C. is a relatively small market, serving its nearly one million residents remains a priority for cannabis businesses.

Successful companies like Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) operating in other markets will be hoping that the reforms being instituted in D.C. result in a more vibrant marijuana industry that is better able to serve its customers.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Marijuana Use Could Trigger Epigenetic Changes, Study Finds

A recent study involving more than 1,000 adults suggests that marijuana use may influence changes in the body’s epigenome, which acts like a series of switches turning genes on or off to regulate bodily functions.

According to Northwestern University epidemiologist Lifang Hou, the study discovered connections between long-term cannabis use and various epigenetic markers over time. While several U.S. states and countries have legalized its use, the full impact on health remains unclear.

According to Hou and her team of researchers from the U.S., about half of all Americans have at least one cannabis experience. Its full health impact is yet unknown, despite numerous U.S. states and other nations having approved its usage.

The research examined individuals who had taken part in a long-term study tracking their cannabis use for two decades. Participants, aged 18 to 30 at the start, provided blood samples twice—once at the 15-year mark and again at 20 years.

Scientists analyzed these samples to detect changes in DNA methylation, a key epigenetic process. DNA methylation involves adding or removing methyl groups from DNA, which alters gene activity without modifying the genetic sequence. These modifications can be triggered by lifestyle and environmental factors and might even be inherited by future generations. Blood biomarkers serve as indicators of both long-term and recent exposures.

Hou explained that previous research had already linked cannabis use to DNA methylation patterns associated with aging. The new study aimed to explore whether specific epigenetic changes related to cannabis use could influence health outcomes.

The researchers compared cumulative and recent marijuana use with DNA methylation indicators in participants’ blood. At the 15-year mark, they identified 22 markers tied to recent cannabis use and 31 linked to long-term use. Five years later, at the 20-year point, they found 132 markers associated with recent use and 16 related to long-term use.

One particular marker repeatedly appeared in the study, which had also been linked to tobacco use. Hou noted that this could suggest a common epigenetic response to both substances. Other marijuana-related epigenetic changes had been previously associated with processes like cell growth, hormone regulation, infections, and neurological conditions such as bipolar disorder and schizophrenia.

However, the study does not confirm that marijuana directly causes these epigenetic changes or leads to specific health problems. Drew Nannini, also a Northwestern University epidemiologist, stressed that more studies are needed to verify the findings across different populations.

There is a lot more that needs to be studied about marijuana, which is why the entire industry, including firms like Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) have for long wanted to see reforms in marijuana policy made at the federal level so that it is easier to conduct studies on this plant and its products. The findings can help to address some of the concerns arising or dispel some misconceptions about this plant.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Nebraska Former Governor, AG Ask Lawmakers to Disregard Ballot Decision Legalizing Medical Cannabis

Nebraska’s Attorney General Mike Hilgers and former Governor Pete Ricketts are asking the state legislature to reject two citizen-led initiatives concerning medical marijuana production, use, and possession. The measures were approved by about 70% of voters in the recent election.

In an opinion piece, Hilgers and Ricketts, now a U.S. Senator, urged lawmakers to disregard the voters’ decision stating that the legislature is not obligated to act on the matter. They expressed concerns over marijuana use, claiming it is harmful, prone to abuse, and unsafe even when used for medical purposes.

Ricketts, a long-time cannabis reform opponent, has previously made extreme claims, including saying that legalizing cannabis could put young people’s lives at risk. The Attorney General’s office warned that if regulators tried to license medical marijuana providers, the state would take legal action, alleging violations of federal law. Legalization opponents have sued to overturn the November election results.

Lawmakers recently heard arguments regarding a proposed law, Legislative Bill 483, which seeks to prevent patients from accessing cannabis in its natural form. Paul Armentano, Deputy Director of NORML, spoke against the measure, emphasizing that voters had clearly expressed their desire for regulated medical marijuana access.

He described the measure as both undemocratic and harmful to patients, explaining that restricting access to only pill or oral forms of cannabis could delay symptom relief for those experiencing nausea, pain, or muscle spasms.

Over 300 people provided testimony opposing LB 483.

Lawmakers also discussed separate measures aimed at refining regulations for medical marijuana access. Supporters of these initiatives, including the advocacy group Nebraskans for Medical Marijuana, gathered at the state capitol to protest efforts to overturn voter-approved measures. Despite extensive debate, no votes were cast on any cannabis-related legislation.

Armentano warned that the state’s attempt to override the election outcome is part of a broader trend seen in GOP-led states. He pointed to Ohio, where lawmakers recently pushed for new restrictions that rolled back voter-approved cannabis legalization, and South Dakota, where a similar attempt to repeal medical marijuana protections narrowly failed.

“In a democracy, different policy perspectives should be debated, and voters’ decisions should be respected,” Armentano stated. “But increasingly, opponents of cannabis reform are working to sideline voters entirely. Regardless of one’s stance on marijuana, these actions should be deeply concerning to anyone who values the democratic process.”

The cannabis industry, including enterprises like Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF), is likely to be concerned by this growing trend in which lawmakers take steps to try and sideline what voters have decided during an election.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Major New Mexico Cannabis Firm Files for Bankruptcy

In spite of the widespread use of cannabis, businesses in the industry have faced significant challenges. Despite the continued growth in retail sales, many brands find it challenging to differentiate themselves in a market that largely views cannabis as a commodity. Even some of the biggest players have filed for bankruptcy due to these difficulties.

A prime example is Planet 13, a well-known cannabis retailer in Las Vegas that features a massive retail space, a restaurant, and a consumption lounge. However, despite its success in Nevada, the company has had trouble replicating that achievement in other locations. No cannabis brand has achieved dominance; rather, most brands resemble generic stores.

One of the key obstacles is pricing. Consumers, who are typically well-informed about cannabis, prioritize the product’s quality—such as its strain and THC content—over brand names. As a result, companies find it difficult to charge premium prices when buyers perceive little difference between brands. Celebrity-backed products, such as those from Tommy Chong or Mike Tyson, often fare better because they leverage name recognition rather than relying on a standalone brand identity.

While demand for marijuana remains strong, brands still face the challenge of convincing consumers to choose them over competitors. This struggle for differentiation has been a major factor in Bright Green Corporation’s recent financial troubles, which recently filed for bankruptcy.

Bright Green Corporation, founded in 2019 and based in New Mexico, specializes in the production of legal marijuana and marijuana extracts. The company operates in manufacturing, research, and medical marijuana production.

Unlike most other cannabis businesses that have gone bankrupt, Bright Green Corporation has found a way forward. The company has reached a Restructuring Support Agreement (RSA) with Lynn Stockwell, a key shareholder, to facilitate a reorganization. Under this agreement, Stockwell will take over as CEO upon court approval. The restructuring plan includes a 1-for-50 reverse stock split and provisions for unsecured creditors to receive a mix of equity and cash.

Stockwell, who also founded Drugs Made in US Acquisition Corp I and II, aims to bring pharmaceutical ingredient manufacturing back to the U.S.

The company is the first publicly traded company in the U.S. to have direct involvement with marijuana cultivation. It plans to collaborate with the HHS to support cannabis research at its New Mexico facility. Additionally, it is exploring a franchise model to expand its agricultural operations in Central New Mexico, East Arizona, and West Texas.

As the marijuana industry matures in different jurisdictions, mergers and acquisitions, bankruptcies and other hallmarks of market consolidation are bound to become increasingly common. It is now up to leading brands like Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) to study the evolving market and position themselves appropriately to benefit from these shifts.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Trump’s DEA Pick Causes Concerns About the Likelihood of Marijuana Rescheduling

President Donald Trump has appointed Terrance Cole to lead the U.S. Drug Enforcement Administration (DEA). Cole, a seasoned DEA professional, is currently serving as a high-ranking law enforcement agent in Virginia.

Trump announced the decision on social media on Tuesday afternoon, Feb. 11. However, Cole’s appointment as the new DEA administrator may not encourage those hoping for the agency to continue the Biden administration’s efforts to reschedule cannabis. His selection follows the withdrawal of Florida sheriff Chad Chronister, who had previously been Trump’s nominee for the position.

Cole’s career with the DEA spans more than 20 years. He retired in 2020 after serving as the acting regional director responsible for overseeing operations in Mexico, Canada, and Central America. Despite Trump expressing support for cannabis rescheduling, Cole’s professional background does not indicate he is likely to push for marijuana policy reforms.

Following his departure from the DEA, Cole became the Secretary of Public Safety and Homeland Security for Virginia, serving in the administration of Governor Glenn Youngkin.

Youngkin, a strong opponent of recreational cannabis sales in Virginia, commended Cole’s nomination. “He will prioritize the security and safety of American citizens as DEA administrator,” Youngkin stated. “This is a great day for Americans and a terrible day for drug dealers.”

If the Senate confirms Cole, he will take over the stalled cannabis rescheduling process. Progress on rescheduling halted in January after pro-cannabis legalization advocates involved in hearings before an agency administrative law judge claimed that the DEA was biased. Critics argue the DEA has intentionally delayed the process and dismissed supporting evidence from states such as Colorado that favor reclassification.

Deciding whether to proceed with the review or abandon it altogether falls solely under the DEA administrator’s authority. The current acting director, Derek Maltz, another long-serving DEA official, has not taken steps to restart the process or signaled any clear intentions regarding the issue.

Capitol Hill political analysts predict that Republican legislators and federal agencies like the DEA would align their marijuana regulations with White House directions. However, all federal legal changes were temporarily put on hold by Trump’s executive order, which was issued on Inauguration Day and required review and approval by department heads chosen by his administration.

In the meantime, Trump’s nominee attorney general, former Florida AG Pam Bondi, has not publicly addressed how she intends to handle key cannabis policy matters, including rescheduling and enforcement guidelines if confirmed.

For now, all that entities like Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) and other industry actors can do is wait and see how the new administration in Washington D.C. chooses to handle the reclassification process that was started under the previous administration.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — DEA Requests Judge to Compel FDA Officials to Testify During Cannabis Reclassification Hearings

The DEA is requesting approval from an agency judge to issue subpoenas compelling officials from the FDA to testify at forthcoming hearings regarding the Biden administration’s proposal to reschedule cannabis.

Friday was the deadline for parties involved in the hearing to submit additional materials, including evidence and witness information, to DEA Judge John Mulrooney as part of the pre-hearing process.

The DEA stated in its filing that it plans to subpoena four FDA officials, even though the HHS previously stated that it wouldn’t voluntarily participate in the proceedings. Additionally, the DEA announced its intention to introduce thousands of comments from the public submitted during the rulemaking process as evidence. This is despite the judge’s prior ruling that public comments are not admissible as evidence, warning the agency against attempting to use them inappropriately.

Judge Mulrooney cautioned that overwhelming the court with inadmissible comments could create the impression of a delay tactic, even if unintentional. The DEA defended its position by arguing that including public comments as evidence is crucial for decision-makers, given their significance to the proposed rulemaking. To address the logistical challenges posed by the volume of comments, the agency requested permission to submit them in electronic form rather than as physical documents.

In its recent filing, the DEA also provided details about the anticipated testimony of the four FDA officials it seeks to subpoena. According to the agency, the officials would provide critical information about the medical and scientific evaluations conducted as part of the HHS Eight-Factor analysis, which forms the foundation of the proposed rescheduling.

The analysis examines several aspects of a substance, including its potential for abuse, known pharmacological effects, current scientific knowledge, history and patterns of misuse, risks to public health, dependence liability, and whether it is a precursor to other controlled substances.

The DEA further explained that witnesses would discuss cannabis’ medical use, including its widespread application in states and the recognition of such use by regulatory entities overseeing medical practice. Additionally, witnesses are expected to address how medical marijuana is currently used in the U.S., despite its designation as a Schedule I drug.

The ongoing proceedings have sparked concerns among marijuana reform advocates about potential bias within the DEA’s handling of the rulemaking process. Some view the agency’s dual role as both the proponent of the proposed rule and the entity overseeing the hearings with skepticism.

The marijuana industry, including enterprises like Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF), looks forward to the next steps of the rescheduling process and the final ruling that will be made on the CSA status of marijuana.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — How Cannabis Firms Can Leverage the Ongoing MJBizCon

Marijuana industry leaders have countless opportunities to form connections and secure business deals at this year’s MJBizCon. MJBizCon 2024 kicked off on Tuesday at the Las Vegas Convention Center, starting with preshow sessions and running through Friday.

To make the most of the world’s largest marijuana business event, it’s essential to arrive with a strategy but also stay adaptable for unforeseen opportunities, according to seasoned attendees who’ve successfully navigated the event.

According to Azuca CEO Kim Sanchez Rael, flexible scheduling is vital since some of the best opportunities come from unexpected encounters. For instance, an impromptu conversation during a preshow lunch at a prior MJBizCon led to a partnership with Wana Brands, a major edibles manufacturer.

Exhibitions have also proven beneficial for Azuca as they provide visibility and a base for meetings. Sanchez notes that being present at a booth allows her company to showcase products, engage with attendees, and even test interest in items not yet launched.

Before the event, Azuca engages in targeted outreach through email campaigns, social media platforms like LinkedIn, and word-of-mouth connections. Sanchez and her team also prearrange meetings with businesses they’re interested in partnering with, ensuring their time at the event is productive.

Another MJBizCon veteran who emphasizes the need for planning is Joe Salome, CEO of Georgia Hemp Co. He recommends researching the exhibitor map in advance to prioritize specific companies and objectives.

However, both Sanchez and Salome agree that maintaining some flexibility is crucial, as chance meetings can result in valuable connections. Salome recounts instances where unplanned interactions at a bar or networking event turned into meaningful business discussions.

Networking at MJBizCon is not limited to the show floor. Preconference breakfasts, lunches, and after-parties are prime opportunities to meet industry professionals. Sanchez Rael advises teams to split up during these events to maximize their networking reach. Salome underscores the importance of attending these gatherings, even when exhaustion sets in, as they often yield unexpected benefits.

MJBizCon is especially valuable for businesses from emerging marijuana markets. Salome points out that in regions like Georgia, where industry infrastructure is still developing, the event offers a chance to connect with suppliers, manufacturers, and other key players. He recalls his first MJBizCon experience in 2015, which helped his company build long-lasting relationships and gain insights from more established markets.

Sometimes, connections made at the event don’t bear fruit until much later. For instance, Jon Spadafora, who launched Flower Union, credits a product introduction at MJBizCon 2022 as the inspiration behind his new edibles line. Conversations with Sanchez on the exhibit floor and at after-parties helped shape his vision, ultimately leading to the creation of a unique product line.

Although MJBizCon is an excellent venue for finding potential partners, industry veterans caution against rushing into agreements. Salome recommends thoroughly evaluating potential collaborators to ensure they align with long-term goals. He suggests holding off on finalizing deals at the event, as emotions can run high in such an environment. Instead, use the convention as an opportunity to gather information and ideas to implement later.

For established firms like Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF), every opportunity to interact with other members of the cannabis industry is welcome since avenues for brand promotion can arise.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Five Highlights from US NASEM Report on Marijuana

Cannabis legalization has made significant progress in the United States, with more than one-half of the states allowing its use for medical or recreational purposes, or both. However, despite these developments, cannabis is still illegal at the federal level.

A recent report from the National Academies of Sciences, Engineering and Medicine (NASEM) highlights the growing divide between federal and state laws, which creates inconsistent policies and could pose risks to public health. Initially, state regulations focused on the business side of cannabis, such as revenue and sales, overlooking public health.

This has led to a situation where policymakers are now scrambling to catch up. The report stresses the importance of federal guidance and consistent national standards to regulate the quality and potency of cannabis, ensuring consumer safety.

Below are five key takeaways from the report:

Cannabis use surpasses alcohol consumption

As per the National Survey on Drug Use and Health, more American adults reported using cannabis nearly every day in 2022 than alcohol, which was the first time marijuana overtook alcohol in terms of frequent use.

During the past 30 years, the number of regular marijuana users has grown significantly, from fewer than a million people in 1992 to almost 18 million in 2022. As cannabis becomes legal in more states, it is easier for people to obtain, with about two-thirds of adults saying the substance is fairly easy to get.

Additionally, the cost of cannabis has decreased, particularly in terms of the cost per unit of THC, the compound responsible for cannabis’ psychoactive effects.

The potency of cannabis products is often undisclosed

Cannabis has progressively grown more THC-concentrated over time. Although smoking dried marijuana flower remains common, there’s been a surge in the popularity of vape oils, edibles and other products.

While some states limit THC levels in certain cannabis products, such as edibles, many other cannabis products remain unregulated. THC concentrations in products such as shatter, wax and dabs can range from 60% to 90%, according to Dr. Yasmin Hurd, head of the Addiction Institute at Mount Sinai.

These high-potency products increase the risk of overconsumption, contributing to more hospital visits and accidents.

Psychoactive hemp products are available in states where cannabis is illegal

Despite marijuana being classified as a schedule I drug under federal law, the 2018 Farm Bill legalized certain hemp-derived products. This has led to an influx of products containing substances, including delta-8 THC and CBD, some of which can still have psychoactive effects.

These hemp-based products are often sold even in states where cannabis remains illegal, though they are largely unregulated. Health officials have raised concerns about the safety of these products, and the report recommends closing this regulatory loophole.

Cannabis research faces significant obstacles

Studying cannabis remains a challenge due to its classification as a schedule I drug, which places strict limitations on researchers. These restrictions make it difficult to conduct studies on the health effects of cannabis.

Even agencies such as the White House Office of National Drug Policy are not permitted to research the impacts of cannabis legalization. The report recommends that Congress remove these barriers and support more extensive research.

Marijuana health risks are often overlooked amid growing public support

Many people view cannabis as less harmful since its legalization, yet awareness of its potential risks remains low. THC has been linked to increased risks of marijuana use disorder, psychosis and suicidal thoughts, especially when consumed in higher doses.

With pro-marijuana advertising becoming more widespread, especially among young adults, there is growing concern about the long-term effects.

The report advocates for public health initiatives to educate the public on the risks, especially targeting vulnerable groups, including children, pregnant women and seniors. Moreover, it calls for better training for marijuana retail staff to provide accurate information to consumers.

This report is likely to draw the interest of cannabis companies such as Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) because it contains numerous insights that can offer glimpses into the discussion points likely to shape future federal policy on marijuana.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Trump Backs Ongoing State, Federal Cannabis Reforms

Donald Trump reaffirmed his support for legalizing recreational cannabis in Florida earlier this week. He also expressed his approval for rescheduling marijuana at the federal level and advocated for removing banking restrictions on state-licensed cannabis businesses.

While he hasn’t endorsed ending the federal ban on marijuana, U.S. presidential candidate Donald Trump has made comments that suggest he’s aware of its potential political influence. His remarks came just ahead of his first debate with Vice President Kamala Harris.

Trump’s support for Amendment 3, which he first hinted at in August, could potentially boost the initiative. If passed, the amendment would allow recreational sales and permit adults aged 21 years of age and older to legally possess up to three ounces of cannabis. The amendment requires 60% voter approval to pass. Polls before Trump’s endorsement suggested it wasn’t certain whether the measure would hit this mark. If successful, Florida would become the 25th state to legalize recreational cannabis.

In addition to endorsing the Florida initiative, Trump expressed support for the Biden administration’s proposal to reclassify cannabis from schedule 1 to 3 under the Controlled Substances Act. Trump commented that this change would help advance research into the medical benefits of marijuana.

Reclassifying cannabis would eliminate some hurdles for medical research and provide financial relief to the marijuana industry. Currently, businesses involved in cannabis cannot claim typical business expenses when filing federal taxes because marijuana is classified under schedule 1. However, this reclassification would not make marijuana legal federally nor would it authorize its use as a prescription drug without specific regulatory approval.

While some uncertainty previously existed about how Trump would approach marijuana in a potential second term, he has shown signs of evolving on this issue. During his previous campaign, he stated that states should have the right to legalize marijuana but also criticized the negative impacts of such policies.

Notably, his administration took steps that contradicted his stance, such as rescinding a memo protecting state-licensed cannabis suppliers and proposing to remove a spending rider preventing federal interference with state medical cannabis programs.

Trump also emphasized his desire to collaborate with Congress to create sensible laws, including securing banking options for state-licensed cannabis businesses. Many financial institutions currently avoid dealing with the marijuana industry due to fear of severe legal consequences, which has left marijuana companies heavily reliant on cash and vulnerable to robbery.

Although legislation to protect banks working with marijuana businesses has faced obstacles in Congress, Trump’s support could potentially push it forward if he were elected.

His evolving position on cannabis legalization may appeal to a broad spectrum of voters. Recent polls indicate that 70% of U.S. adults, including majorities across both political parties, believe cannabis should be legalized.

Trump’s evolving stance on cannabis reform, while not as far-reaching as complete federal legalization, may still have significant implications for his political strategy. What the cannabis industry and enterprises such as Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) hope for is for tangle reforms to be made at the federal level so that the growth of the industry can face fewer hurdles.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Americans’ Opinions of Marijuana’s Effects Decline Further, Poll Shows

Americans’ perceptions of cannabis’ effects have become less optimistic over the last two years; a slight majority now worry that most users (51%) and society as a whole are harmed by it. This is a significant change from 2022, when opinions were more evenly divided and more people (53%) thought marijuana had a good impact on users, while only 45% thought it had a negative one.

These new insights are based on a Gallup Consumption Habits survey conducted from July 1 to July 21, 2024, which shows that a sizable portion of different demographics still have favorable opinions of marijuana. This group comprises those who have personally experimented with marijuana, Democrats, young people aged 18 to 34 years of age, and those who seldom or never attend religious events.

Those who have never tried cannabis, Republicans, those who attend religious services regularly, and those who are 55 years of age or older, on the other hand, have different opinions and generally believe that most cannabis users have been negatively impacted. Notably, opinions are more divided among independents and people aged between 35 and 54 years old.

A pattern that is evident in all of these groups is a decline in the perception of cannabis’ beneficial effects as compared to prior years. Furthermore, fewer than one-half of respondents in each of these categories now believe that cannabis has a beneficial impact on society.

In a different section of the poll, Gallup asked respondents to rank the level of danger associated with chewing tobacco, cigarettes, e-cigarettes, pipes, cigars, nicotine patches, cannabis and alcohol.

While all eight narcotics are viewed as “somewhat” or “very” hazardous by most Americans, marijuana is the least of the lot. The majority of respondents — roughly two-thirds — believe that marijuana is either extremely (26%) or moderately (40%) dangerous. This pales in comparison to the broad consensus that products such as e-cigarettes, cigarettes and chewing tobacco are harmful; more than 90% of American people consider these to be dangerous, with the majority believing they are extremely problematic.

Public sentiment on the dangers of cannabis has shifted slightly since 2023, with the percentage of those who see it as very harmful rising from 23% to 26%, and those considering it somewhat harmful shifting from 35% to 40%.

In addition, 13% of American adults today report smoking cannabis, a small decrease from the 17% noted in 2023, whereas 12% of individuals use edibles. In addition, 7% of American adults prefer e-cigarettes or vaping, and 58% of individuals say they drink alcohol, making it the most commonly taken drug.

Major cannabis companies such as Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) are likely to analyze these poll results and see what hidden insights they can glean from the data.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com